Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Director's Dealing 2021

Mar 1, 2021

29831_dirs_2021-03-01_8270c7d7-8911-4d70-b4b9-3c11fca90c69.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2021-02-25

Reporting Person: MACKENZIE ALEXANDER R (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-25 Common Stock A 26732.0000 $0.0000 Acquired 137727.0000 Direct
2021-02-25 Common Stock F 14227.0000 $33.8200 Disposed 123500.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-25 Stock Appreciation Rights $33.8200 A 84279.0000 Acquired 2026-02-25 Common Stock (84279.0000) Direct
2021-02-25 Stock Appreciation Rights $33.8200 A 72820.0000 Acquired 2028-02-25 Common Stock (72820.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 10106.0000 Indirect

Footnotes

F1: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).

F3: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F4: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.